Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment.

Tytuł:
Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment.
Autorzy:
Pepper I; Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States.
Vinik A; Strelitz Diabetes Center, Eastern Virginia Medical School, Norfolk, VA, United States.
Lattanzio F; Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States.
McPheat W; Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States.
Dobrian A; Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States.
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2019 May 17; Vol. 10, pp. 311. Date of Electronic Publication: 2019 May 17 (Print Publication: 2019).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Research Foundation]
References:
Behav Pharmacol. 1998 Mar;9(2):179-81. (PMID: 10065938)
Neuroscience. 1999;92(1):377-87. (PMID: 10392859)
Am J Physiol Regul Integr Comp Physiol. 2000 Oct;279(4):R1277-81. (PMID: 11003993)
Nature. 2001 Apr 12;410(6830):822-5. (PMID: 11298451)
N Engl J Med. 2001 May 3;344(18):1343-50. (PMID: 11333990)
J Comp Neurol. 2001 Aug 6;436(4):423-9. (PMID: 11447587)
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):353-61. (PMID: 12052049)
Cardiovasc Diabetol. 2002 Apr 08;1:1. (PMID: 12119059)
Pharmacol Ther. 2002 Aug;95(2):185-90. (PMID: 12182965)
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53. (PMID: 12399252)
Gastroenterology. 2002 Nov;123(5):1705-25. (PMID: 12404245)
Gene. 2003 Jan 2;302(1-2):95-101. (PMID: 12527200)
Gene. 2003 Jul 17;312:297-303. (PMID: 12909367)
Am J Hum Genet. 1962 Dec;14:353-62. (PMID: 13937884)
J Am Coll Nutr. 2003 Oct;22(5):331-9. (PMID: 14559925)
Science. 1992 Dec 18;258(5090):1946-9. (PMID: 1470919)
J Pharmacol Exp Ther. 2005 Feb;312(2):554-60. (PMID: 15340017)
FEBS Lett. 2005 Jan 3;579(1):259-64. (PMID: 15620723)
J Clin Invest. 2005 May;115(5):1298-305. (PMID: 15864349)
Diabetes. 1992 Jun;41(6):715-22. (PMID: 1587398)
J Neurochem. 2005 Jun;93(5):1141-56. (PMID: 15934935)
Circulation. 2005 Oct 25;112(17):2735-52. (PMID: 16157765)
Life Sci. 2006 May 30;79(1):30-7. (PMID: 16434061)
FEBS Lett. 2006 Apr 3;580(8):1941-5. (PMID: 16519888)
J Evol Biol. 2006 Mar;19(2):366-73. (PMID: 16599912)
J Exp Biol. 2006 May;209(Pt 9):1630-8. (PMID: 16621944)
Postgrad Med J. 2006 May;82(967):315-22. (PMID: 16679470)
J Am Coll Cardiol. 2006 May 16;47(10):1919-26. (PMID: 16697306)
J Clin Invest. 2006 Jul;116(7):1756-60. (PMID: 16823472)
Trends Endocrinol Metab. 2007 Jan-Feb;18(1):27-37. (PMID: 17141520)
Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33. (PMID: 17223076)
Mol Pharmacol. 2007 Jun;71(6):1445-56. (PMID: 17327463)
Cell. 2007 Oct 19;131(2):242-56. (PMID: 17956727)
Am J Physiol Regul Integr Comp Physiol. 2008 Aug;295(2):R417-28. (PMID: 18550869)
Brain Res. 2008 Jul 30;1222:141-8. (PMID: 18582849)
Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):345-69. (PMID: 18654765)
J Clin Invest. 2008 Sep;118(9):3160-9. (PMID: 18677409)
Diabetes Care. 2008 Nov;31(11):2169-76. (PMID: 18678611)
Diabetologia. 2009 Feb;52(2):213-7. (PMID: 18972095)
Diabetologia. 2009 Apr;52(4):664-74. (PMID: 19089403)
Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R476-84. (PMID: 19109369)
Metabolism. 2009 Mar;58(3):361-7. (PMID: 19217452)
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):87-102. (PMID: 19285263)
Neuroreport. 2009 Apr 22;20(6):595-9. (PMID: 19293731)
PLoS One. 2009;4(3):e5092. (PMID: 19333392)
Diabetes. 2009 Jul;58(7):1526-31. (PMID: 19401428)
Neuropharmacology. 2009 Aug;57(2):88-96. (PMID: 19501110)
Obes Rev. 2010 Jan;11(1):11-8. (PMID: 19656312)
Comp Biochem Physiol A Mol Integr Physiol. 2010 Feb;155(2):134-8. (PMID: 19879954)
Diabetes Obes Metab. 2010 Feb;12(2):158-66. (PMID: 19895638)
Metabolism. 2010 May;59(5):734-41. (PMID: 19919870)
J Neurosci. 1991 Feb;11(2):563-83. (PMID: 1992016)
Diabetes Care. 2010 Mar;33(3):605-7. (PMID: 20009090)
Curr Med Chem. 2010;17(14):1382-93. (PMID: 20166926)
Cell Metab. 2010 Apr 7;11(4):273-85. (PMID: 20374960)
Eur J Pharmacol. 2010 Jul 10;637(1-3):62-9. (PMID: 20399204)
Eur J Pharmacol. 2010 Jul 10;637(1-3):70-6. (PMID: 20406631)
Br J Pharmacol. 2010 Jun;160(3):530-43. (PMID: 20590563)
J Neurosci. 2010 Jun 30;30(26):8965-73. (PMID: 20592217)
Front Neuroendocrinol. 2010 Jul;31(3):377-93. (PMID: 20600241)
Mol Syst Biol. 2010 Jul;6:392. (PMID: 20664638)
Lancet. 2010 Aug 14;376(9740):517-23. (PMID: 20709233)
Trends Endocrinol Metab. 2010 Nov;21(11):643-51. (PMID: 20846876)
PLoS One. 2010 Dec 01;5(12):e14197. (PMID: 21152018)
J Clin Endocrinol Metab. 2011 Mar;96(3):787-91. (PMID: 21177788)
J Clin Pharm Ther. 2011 Feb;36(1):10-8. (PMID: 21198716)
Nutr Metab (Lond). 2011 Jan 30;8(1):7. (PMID: 21276269)
Int J Obes (Lond). 2011 Nov;35(11):1377-84. (PMID: 21326208)
PLoS One. 2011 Feb 25;6(2):e17261. (PMID: 21364873)
Handb Exp Pharmacol. 2011;(203):75-104. (PMID: 21484568)
J Neurosci. 2011 Jul 20;31(29):10506-15. (PMID: 21775596)
Lipids Health Dis. 2011 Oct 28;10:194. (PMID: 22035053)
Mol Pharm. 2012 Mar 5;9(3):570-80. (PMID: 22224483)
J Obes. 2012;2012:258624. (PMID: 22235369)
J Physiol. 2012 May 15;590(10):2203-12. (PMID: 22289914)
Gastroenterology. 2012 May;142(5):1218-1228.e1. (PMID: 22307032)
Am J Physiol Endocrinol Metab. 2012 May 1;302(10):E1261-8. (PMID: 22374758)
J Exp Biol. 2012 Apr 15;215(Pt 8):1331-6. (PMID: 22442371)
PLoS One. 2012;7(5):e36569. (PMID: 22574183)
Pharmacol Biochem Behav. 2012 Aug;102(2):335-43. (PMID: 22609797)
Trends Neurosci. 2012 Jul;35(7):403-11. (PMID: 22622030)
Cell Metab. 2012 Aug 8;16(2):167-79. (PMID: 22841573)
PLoS One. 2012;7(7):e42399. (PMID: 22860123)
Br J Pharmacol. 2012 Dec;167(8):1583-95. (PMID: 22924606)
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80. (PMID: 22959249)
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3201-15. (PMID: 23108540)
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3216-28. (PMID: 23108541)
Transgenic Res. 2013 Aug;22(4):823-38. (PMID: 23315130)
Cell Metab. 2013 Apr 2;17(4):475-90. (PMID: 23562074)
Br J Clin Pharmacol. 2013 Dec;76(6):846-57. (PMID: 23601084)
Obesity (Silver Spring). 2014 Jan;22(1):211-6. (PMID: 23616305)
Am J Med. 2013 Jul;126(7):583-9. (PMID: 23684393)
Lipids Health Dis. 2013 May 27;12:78. (PMID: 23706001)
PLoS One. 2013 Jun 25;8(6):e67791. (PMID: 23825686)
Proc Biol Sci. 2013 Jul 17;280(1766):20130836. (PMID: 23864595)
Placenta. 2013 Nov;34(11):983-9. (PMID: 24008071)
Front Neurosci. 2013 Oct 07;7:177. (PMID: 24109426)
PLoS One. 2014 Mar 12;9(3):e89566. (PMID: 24622769)
Cell Metab. 2014 Jun 3;19(6):910-25. (PMID: 24630812)
Neurosci Res. 2014 Sep;86:25-36. (PMID: 24671134)
Lipids Health Dis. 2014 Apr 23;13:71. (PMID: 24758278)
Biochim Biophys Acta. 2015 Feb;1852(2):232-42. (PMID: 24997452)
Nutr Diabetes. 2014 Jul 14;4:e127. (PMID: 25027795)
J Clin Endocrinol Metab. 2015 Jan;100(1):220-6. (PMID: 25368979)
Gerontology. 2015;61(3):211-7. (PMID: 25531079)
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):285-90. (PMID: 25535367)
BMB Rep. 2015 Apr;48(4):229-33. (PMID: 25560696)
Cell. 2015 Jan 15;160(1-2):88-104. (PMID: 25594176)
J Hepatol. 2015 Jun;62(6):1382-90. (PMID: 25595882)
J Clin Invest. 2015 Mar 2;125(3):891-8. (PMID: 25642767)
Mol Biol Evol. 2015 Apr;32(4):835-45. (PMID: 25739733)
Drugs. 2015 Jun;75(9):935-45. (PMID: 25985865)
Br J Pharmacol. 2016 Apr;173(7):1116-27. (PMID: 26076890)
Am J Physiol Endocrinol Metab. 2015 Oct 15;309(8):E747-58. (PMID: 26306598)
Trends Endocrinol Metab. 2015 Oct;26(10):524-537. (PMID: 26412154)
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6185-94. (PMID: 26494286)
PLoS One. 2015 Nov 11;10(11):e0142728. (PMID: 26561012)
Sleep. 2016 Mar 01;39(3):653-64. (PMID: 26612385)
Nat Neurosci. 2016 Feb;19(2):206-19. (PMID: 26814590)
J Physiol Biochem. 2016 Jun;72(2):183-99. (PMID: 26880264)
Development. 2016 Feb 15;143(4):609-22. (PMID: 26884397)
Nutrients. 2016 Mar 02;8(3):128. (PMID: 26950145)
Endocrinology. 2016 May;157(5):1751-63. (PMID: 27014939)
Diabetes Metab J. 2016 Apr;40(2):89-98. (PMID: 27126880)
Sci Rep. 2016 Sep 19;6:33302. (PMID: 27641999)
Neuroendocrinology. 2017;104(4):330-346. (PMID: 27728914)
Cell. 2016 Oct 20;167(3):750-762.e14. (PMID: 27768894)
PLoS One. 2016 Nov 2;11(11):e0165432. (PMID: 27806128)
Br J Pharmacol. 2017 Jun;174(11):1464-1483. (PMID: 27891602)
Physiol Behav. 2017 Mar 15;171:32-39. (PMID: 28065722)
J Physiol Biochem. 2016 Aug;73(3):349-357. (PMID: 28337718)
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jul 13;85:180-188. (PMID: 28392485)
AAPS J. 2017 Jul;19(4):921-930. (PMID: 28397097)
Diabetes Res Clin Pract. 2017 Jun;128:40-50. (PMID: 28437734)
JCI Insight. 2017 May 4;2(9):null. (PMID: 28469090)
Nature. 2017 Jun 7;546(7657):293-296. (PMID: 28593967)
Neuropsychopharmacology. 2018 Jan;43(1):155-172. (PMID: 28653665)
Clin Diabetes Endocrinol. 2017 Jan 18;3:1. (PMID: 28702255)
Methods Enzymol. 2017;593:199-215. (PMID: 28750803)
Sci Rep. 2017 Aug 8;7(1):7558. (PMID: 28790443)
Int J Mol Sci. 2017 Aug 24;18(9):null. (PMID: 28837063)
Mol Metab. 2017 Oct;6(10):1113-1125. (PMID: 29031713)
J Nutr Biochem. 2018 Jan;51:56-68. (PMID: 29102876)
Br J Nutr. 2017 Nov;118(10):788-803. (PMID: 29110748)
Diabetol Metab Syndr. 2017 Nov 2;9:88. (PMID: 29118852)
Am J Physiol Endocrinol Metab. 2018 Apr 1;314(4):E322-E333. (PMID: 29138223)
Sci Rep. 2017 Nov 15;7(1):15645. (PMID: 29142285)
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1077-1087. (PMID: 29300902)
PLoS One. 2018 Jan 5;13(1):e0190897. (PMID: 29304078)
Nutr Diabetes. 2018 Jan 17;8(1):6. (PMID: 29343706)
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):320-332. (PMID: 29413441)
J Diabetes. 2018 Sep;10(9):744-752. (PMID: 29508937)
Front Pharmacol. 2018 Mar 20;9:156. (PMID: 29615900)
Int J Biochem Cell Biol. 2018 Jun;99:114-124. (PMID: 29626639)
Diabetes. 1988 Dec;37(12):1595-607. (PMID: 3056758)
Front Pharmacol. 2019 Mar 20;10:207. (PMID: 30949045)
Biochem Pharmacol. 1995 Jun 29;50(1):83-90. (PMID: 7605349)
Neuropharmacology. 1994 Mar-Apr;33(3-4):319-24. (PMID: 7984268)
J Appl Physiol (1985). 1998 Apr;84(4):1311-5. (PMID: 9516198)
Contributed Indexing:
Keywords: NAFLD; cannabinoids; energy balance; evolution; obesity; type 2 diabetes
Entry Date(s):
Date Created: 20190604 Latest Revision: 20200225
Update Code:
20240105
PubMed Central ID:
PMC6533883
DOI:
10.3389/fendo.2019.00311
PMID:
31156558
Czasopismo naukowe
When primitive vertebrates evolved from ancestral members of the animal kingdom and acquired complex locomotive and neurological toolsets, a constant supply of energy became necessary for their continued survival. To help fulfill this need, the endocannabinoid (eCB) system transformed drastically with the addition of the cannabinoid-1 receptor (CB1R) to its gene repertoire. This established an eCB/CB1R signaling mechanism responsible for governing the whole organism's energy balance, with its activation triggering a shift toward energy intake and storage in the brain and the peripheral organs (i.e., liver and adipose). Although this function was of primal importance for humans during their pre-historic existence as hunter-gatherers, it became expendable following the successive lifestyle shifts of the Agricultural and Industrial Revolutions. Modernization of the world has further increased food availability and decreased energy expenditure, thus shifting the eCB/CB1R system into a state of hyperactive deregulated signaling that contributes to the 21st century metabolic disease pandemic. Studies from the literature supporting this perspective come from a variety of disciplines, including biochemistry, human medicine, evolutionary/comparative biology, anthropology, and developmental biology. Consideration of both biological and cultural evolution justifies the design of improved pharmacological treatments for obesity and Type 2 diabetes (T2D) that focus on peripheral CB1R antagonism. Blockade of peripheral CB1Rs, which universally promote energy conservation across the vertebrate lineage, represents an evolutionary medicine strategy for clinical management of present-day metabolic disorders.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies